Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 62% Improvement Relative Risk c19ivermectin.com Bryant et al. Ivermectin for COVID-19 META ANALYSIS Favors ivermectin Favors control
Bryant, ivermectin meta analysis: 62% lower mortality [p=0.005] https://c19p.org/bryant
copied to clipboard
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Bryant et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001402 (preprint 3/11/21) (meta analysis)
17 Jun 2021    Source   PDF   Share   Tweet
Systematic review, meta analysis, and trial sequential analysis of 24 RCTs finding mortality RR 0.38 [0.19-0.73].
An update notes potentially inaccurate data collection and/or reporting in some sources [journals.lww.com].
Currently there are 82 ivermectin for COVID-19 studies, showing 53% [39‑64%] lower mortality, 31% [11‑46%] lower ventilation, 54% [36‑67%] lower ICU admission, 38% [24‑49%] lower hospitalization, and 78% [67‑86%] lower cases.
risk of death, 62.0% lower, RR 0.38, p = 0.005.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bryant et al., 6/17/2021, peer-reviewed, 7 authors.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit